text
text
Block

Search the toolbox

Research question

  • Define a question

    The definition of the research question is key to research design. All research must have a primary question, clearly stated in advance, and founded on a systematic review of what is already known. Researchers who plan studies without reviewing what has been done, risk performing research for which the answer is already known or exposing participants to ineffective or an inferior treatment.

  • Develop a protocol

    The ICH GCP E6 (R3) (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use- Good Clinical Practice) guideline defines the protocol as “A document that describes the objective(s), design, methodology, statistical considerations and organisation of a trial. The protocol usually also gives the background and rationale for the trial, but these could be provided in other protocol-referenced documents”

  • Identify a sponsor

    The ICH for Good Clinical Practice guidelines E6 (R3) and the Clinical Trials Regulation (536/2014), define a sponsor as “an individual, company, institution or organisation which takes responsibility for the initiation, for the management and for setting up the financing of the clinical trial”

  • Identify a funder

    Industry-initiated clinical trials are financially supported by the industry. The principal investigator (PI) salary and the costs associated with running the trial are all covered by the pharmaceutical company that conceived the clinical trial. In investigator-initiated trials (IIT), however, usually is the PI who applies for funding through research programs and government grants to fund their conceived research project.

Plan

  • Risk assessment

    Risk assessment is a systematic process for identifying and evaluating events that could affect the achievement of clinical study´s objectives related to quality, safety, timelines and budget, positively or negatively.  

  • Trials Management Plan

    The purpose of a Project Management Plan (PMP) in a clinical trial is to define the scope, outline responsibilities and describe key steps of the clinical trial process.

  • Data Management Plan

    DMP is a written document that describes the plans for collection and management of data throughout the lifecycle of a clinical trial. The DMP describes which clinical data will be acquired and how it will be handled, stored, checked for consistency and plausibility, and made available for the final analysis and further research after the end of the project.

Execute

  • Trial Management

    Trial management is the process of ensuring that a trial is run effectively and within budget and timelines.

  • Regulatory submission

    Prior to initiating a clinical trial, researchers must obtain approval from National Competent Authorities (NCA) and ethics committees.

  • Quality Management

    The sponsor should implement a system to manage quality throughout all stages of the trial process, in particularly on trial activities essential to ensuring human subject protection and the reliability of trial results.  

  • Safety reporting

    The sponsor is responsible for the ongoing safety evaluation of the Investigational Medicinal Product(s) used in a Clinical Trial

  • Data management

    A process that begins with conception and design of the clinical trial, continues through data capture and analysis to publication, data archiving and data sharing with the broader scientific community. The Data Management Plan (DMP) describes the procedures for data collection and management  throughout the lifecycle of a clinical trial. 

  • Investigational Product

    An investigational product (IP), as defined by the ICH is a pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, including a product with a marketing authorization when used or assembled (formulated or packaged) in a way different from the approved form, or when used for an unapproved indication, or when used to gain further information about an approved use.

  • Laboratory Processes

    The analysis of samples collected from subjects participating in clinical trials forms a key part of the clinical trials process. Sample analysis or evaluation provides important data on a range of endpoints which is used, for example, to assess the pharmacokinetic profile of investigational medicinal products and to monitor their safety and efficacy.

Analyse

  • Statistical Analysis Plan

    The SAP is intended to be a comprehensive document that contains a detailed and technical description of the principal features of the  statistical analysis outlined in the protocol including detailed procedures for executing the statistical analysis of the primary and secondary endpoints and other data.

End of trial

  • Trial report

    A Clinical Study Report (CSR) is a is a key document that describes the methodology and results of a clinical trial in drug development.

  • Archiving

    The documents which individually and collectively permit evaluation of the conduct of a clinical trial and the quality of the data produced are defined as essential documents according to the ICH Good Clinical Practice.

  • Dissemination

    After each clinical trial finishes, the trial sponsor will compile a detailed clinical study report (CSR), which follows a format laid down by the regulatory authorities. Access to the complete CSR is usually limited to the sponsor and the regulatory authorities that are assessing the marketing authorisation application.

Block

Dissemination

After each clinical trial finishes, the trial sponsor will compile a detailed clinical study report (CSR), which follows a format laid down by the regulatory authorities. Access to the complete CSR is usually limited to the sponsor and the regulatory authorities that are assessing the marketing authorisation application.

Content
Chapo

The CONSORT Extension for Reporting N-of-1 Trials (CENT) provides reporting recommendations to improve transparency, completeness and consistency in the publication of N-of-1 trial results. It supports researchers in communicating individual-level trial designs, interventions, outcomes and analyses. The tool is particularly relevant for rare disease research, where N-of-1 trials may provide valuable evidence when conventional clinical trial designs are challenging due to small patient populations and disease heterogeneity.

Category
  • End of trial
  • Dissemination
Chapo

The European Commission's public registry for clinical trials, through the Clinical Trials Information System (CTIS), plays a central role in disseminating the results of clinical trials by making key trial information publicly accessible throughout the trial lifecycle. CTIS provides a single public portal where patients, healthcare professionals, researchers, and the public can search for information on clinical trials conducted under the EU Clinical Trials Regulation (CTR).
Sponsors are required to submit summary results, including a layperson summary, within specified timelines after the end of a clinical trial. These summaries are published in CTIS, increasing transparency and enabling wider dissemination of findings.

Category
  • End of trial
  • Dissemination
Chapo

Online tutorial from the European Patients’ Academy on Therapeutic Innovation (EUPATI) that explains how clinical trial results are recorded and reported once a study has finished. It introduces the clinical study report format and the main routes used to disseminate trial findings, including regulatory documents, trial registries, scientific journals, conferences, patient organisation websites and news media. A downloadable presentation is provided for reuse in training and education.
 

Category
  • End of trial
  • Dissemination
Chapo

Guidance from the European Commission on preparing summaries of clinical trial results for laypersons, in line with Clinical Trials Regulation (EU) No. 536/2014. Good Lay Summary Practice (GLSP) provides recommendations on planning, writing, translating and disseminating plain‑language summaries of clinical trial results, covering all ten mandatory lay summary content elements specified in Annex V of the Regulation. It aims to support transparent, understandable communication of trial outcomes to participants and the public. GLSP is mandatory guidance for interventional clinical trials with medicinal products conducted in the EU/EEA and published in EudraLex Volume 10.

Category
  • End of trial
  • Dissemination
Chapo

TranspariMED’s Clinical trial transparency tools page collates practical tools, manuals, workshop materials and case studies that universities and other institutions can use to strengthen clinical trial registration and results reporting, improve registry data quality, and embed transparency within institutional policies and audit practices.

Category
  • End of trial
  • Dissemination
Chapo

COBWEB (CONSORT‑based WEB tool) is a user friendly online manuscript‑writing aid that guides authors through drafting randomised controlled trial reports in line with the Consolidated Standards of Reporting Trials (CONSORT) and its extensions. Developed by clinical epidemiologists, it helps users write, edit, share and export randomised trial manuscripts structured around CONSORT checklist items. The tool provides tailored templates for different trial designs and intervention types, with bullet‑point prompts and examples of good reporting for each item, consolidating relevant CONSORT guidance into a single, editable document.

Category
  • End of trial
  • Dissemination
Chapo

The CONSORT-C Extension provides recommendations to improve the reporting and dissemination of randomised clinical trials involving children and adolescents. It complements the general CONSORT Statement by addressing paediatric-specific considerations and supporting transparent reporting of trial design, interventions, outcomes and results. The tool is particularly relevant for paediatric rare disease trials, where small populations and limited evidence require high-quality reporting to maximise the value and usability of clinical research findings.

Category
  • End of trial
  • Dissemination
Chapo

The CONSORT-Outcomes 2022 extension provides harmonised, evidence‑ and consensus‑based guidance for reporting outcomes in randomised clinical trial reports, adding 17 outcome‑specific items to the CONSORT 2010 (and updated CONSORT 2025) checklist to ensure that outcomes are fully defined, justified, assessed, analysed and reported in ways that enhance trial utility, replicability and transparency, and limit selective non‑reporting of trial results.

Category
  • End of trial
  • Dissemination
Chapo

CONSORT 2025 is the updated Consolidated Standards of Reporting Trials statement, providing a 30‑item checklist and participant flow diagram that set out the minimum information required when reporting randomised trials. It supersedes earlier CONSORT versions (1996, 2001, 2010) and reflects new methodological evidence, open science practices and user feedback. Developed through a scoping review, international Delphi survey (317 participants in round 1) and expert consensus meeting, it aims to improve clarity, completeness and transparency of trial reports. The guideline is endorsed by major journals and editorial organisations and is associated with more complete reporting in journals that require its use. Authors, editors, reviewers and other users are encouraged to use CONSORT 2025 alongside the detailed explanation and elaboration document and expanded checklist when preparing or appraising reports of randomised trials.

Category
  • End of trial
  • Dissemination